Bennink R, Van Poppel H, Billen J, Decoster M, Baert L, Mortelmans L, Blanckaert N
Department of Nuclear Medicine, University Hospital Gasthuisberg, KU Leuven, Belgium.
Anticancer Res. 1999 Jul-Aug;19(4A):2609-13.
Tissue polypeptide antigen (TPA) is a serological tumor marker, measuring cytokeratin 8, 18 and 19, used in the follow-up of non squamous epithelium- and derived neoplasms. It has been demonstrated that TPA is reliable in the monitoring of the efficacy of a curative or palliative treatment of bladder cancer. Recently, a monoclonal antibody-based assay for TPA (TPA-M) has been developed, which seems to be equivalent to the polyclonal-based assay. The aim of the study was to assess the superiority of the monoclonal to the polyclonal test in patients with bladder carcinoma. The value of tissue polypeptide antigen was therefore measured both with TPA and TPA-M IRMA. A correlation coefficient of 0.96 was obtained. Precision testing showed a lower overall variability of TPA-M. Since both tests correlate well and TPA-M testing is more precise, faster and easy to perform, we conclude a superiority of TPA-M and advise the monoclonal test as best suited for clinical use in the follow-up of bladder cancer patients with poorly differentiated superficial, locally advanced or systemic disease after curative or palliative therapy.
组织多肽抗原（TPA）是一种血清学肿瘤标志物，可检测细胞角蛋白8、18和19，用于非鳞状上皮来源肿瘤的随访。已经证明，TPA在监测膀胱癌根治性或姑息性治疗的疗效方面是可靠的。最近，一种基于单克隆抗体的TPA检测方法（TPA-M）已被开发出来，它似乎与基于多克隆抗体的检测方法相当。该研究的目的是评估单克隆检测相对于多克隆检测在膀胱癌患者中的优越性。因此，采用TPA和TPA-M免疫放射分析方法测量组织多肽抗原的值。获得的相关系数为0.96。精密度测试显示TPA-M的总体变异性较低。由于两种检测方法相关性良好，且TPA-M检测更精确、更快且易于操作，我们得出TPA-M更具优越性的结论，并建议将单克隆检测作为最适合用于随访根治性或姑息性治疗后低分化浅表性、局部晚期或全身性疾病的膀胱癌患者临床使用的检测方法。
